Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Eli Lilly is advancing toward a 2027 regulatory filing for retatrutide following successful Phase 3 obesity trial results.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Eli Lilly has announced that its triple agonist, retatrutide, succeeded in two additional Phase 3 obesity trials. The drug demonstrated significant improvements in A1C and weight, with Forbes reporting an average weight loss of 56 pounds.
Coverage from Bloomberg, CNBC, the Wall Street Journal, and Eli Lilly and Company emphasizes that the drug has cleared critical hurdles. The company is now preparing applications for the next-generation weight-loss treatment.
According to CNBC, the company intends to file for approval of the obesity drug in 2027.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What is the name of the drug being developed?
The drug is a triple agonist called retatrutide.
What were the results of the Phase 3 trials?
The trials showed significant improvements in weight and A1C, with an average weight loss of 56 pounds.
When does Eli Lilly plan to file for approval?
The company stated it will file for approval in 2027.
Coverage (6)
- New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit STAT · 5h ago
- Eli Lilly’s Next-Generation Weight-Loss Shot Clears Another Hurdle Bloomberg.com · 5h ago
- Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials CNBC · 5h ago
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Eli Lilly and Company · 5h ago
- Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average Forbes · 5h ago
- Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data WSJ · 5h ago
Topics
Related trends
Why Arrowhead Shot Sky-High, While Ionis Toppled
Arrowhead Pharmaceuticals shares surged following positive Phase 3 trial data for its triglyceride-lowering drug, creating a divergent market move with Ionis.
GLP-1 use rising rapidly among US adolescents and young adults, study finds
GLP-1 weight-loss medications are seeing a rapid surge in use among U.S. adolescents and young adults, coinciding with a decline in bariatric surgeries.
More young women in their 20s are getting type 2 diabetes
Health officials are warning of a 'health time bomb' as Type 2 diabetes cases surge among women in their 20s and those under 40.
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the rival company used false and misleading advertising regarding weight-loss drug efficacy.
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the use of misleading and deceptive advertising for GLP-1 weight-loss drugs.
This GLP-1 retreat changed how I think about weight loss
GLP-1 medications are sparking broader conversations about weight loss retreats, medical benefits beyond weight, and the psychological impact of stigma.